Form D · Biotechnology

LifeMine Therapeutics, Inc.

Cambridge, MA · CIK 0001686955

Offering snapshot reported Mar 29, 2019 · SEC filing

Reported sold: $70.1M
Investors reported: 10
Minimum accepted: $0
First sale: Sep 15, 2017

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$25,074,131 → $70,074,079
Reported investors9 → 10

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 29, 2019	Amendment	$70,074,079	$44,999,948vs Sep 27, 2017	10	SEC filing
Sep 27, 2017	Initial	$25,074,131	No comparison	9	SEC filing
Oct 11, 2016	Initial	$5,000,500	No comparison	1	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-295461

Source: Form D, filed Mar 29, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Yanling Cao	Director
Hingge Hsu	Executive
Edward Hu	Director
Richard Klausner	Director
Wei Li	Director
Jim Tananbaum	Director
Gregory L. Verdine	Director, Executive
Krishna Yeshwant	Director
Wei Qing Zhou	Executive
Weiqing Zhou	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

100 Acorn Park, 6th Floor
Cambridge, MA, 02140